Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nasal calcitonin

S L Silverman1

  • 1West Los Angeles VA Medical Center, UCLA 90073, USA.

Endocrine
|April 1, 1997
PubMed
Summary
This summary is machine-generated.

Nasal calcitonin is a new osteoporosis treatment that boosts bone mass and is well-tolerated. While fracture data is pending, it shows promise for bone pain and certain osteoporosis types.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Study of the Disputed Point in Local Anesthesia.

The Dental register·2021
Same author

Factors associated with the contemplative stage of readiness to initiate osteoporosis treatment.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2020
Same author

Fracture healing: a consensus report from the International Osteoporosis Foundation Fracture Working Group.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2016
Same author

Bisphosphonate drug holidays: we reap what we sow.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2015
Same author

Comorbidity indices for clinical trials: adaptation of two existing indices for use with the FREEDOM trial in women with postmenopausal osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2015
Same author

Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2014
Same journal

Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation.

Endocrine·2026
Same journal

Effects of a single-dose denosumab on glucose and lipid homeostasis in young infertile men.

Endocrine·2026
Same journal

Ultrasound-guided thermal ablation for papillary thyroid microcarcinoma with calcifications: short-term imaging outcomes.

Endocrine·2026
Same journal

Diabetic gastroparesis: pathophysiology and impact on insulin timing choices.

Endocrine·2026
Same journal

Liquid biopsies for BRAF V600E assessment and monitoring in anaplastic thyroid carcinoma: a real-world study of a tertiary cancer center.

Endocrine·2026
Same journal

Interpreting the TIR 3B nomogram as a rule-in rather than rule-out tool.

Endocrine·2026
See all related articles

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Pharmacology

Background:

  • Osteoporosis is a significant public health concern, increasing fracture risk.
  • Established treatments have limitations or side effects.
  • Nasal calcitonin presents a new therapeutic option.

Purpose of the Study:

  • To review the efficacy and safety of newly approved nasal calcitonin for established osteoporosis.
  • To explore potential benefits in specific patient populations and conditions.

Main Methods:

  • Review of clinical data and preliminary findings on nasal calcitonin.
  • Analysis of safety and tolerability profiles.
  • Assessment of potential applications and dosing.

Main Results:

Related Experiment Videos

  • Nasal calcitonin increases lumbar spine bone mass in established osteoporosis.
  • The treatment is reported to be safe and well-tolerated.
  • Preliminary data suggests potential analgesic effects and benefits in specific osteoporosis subtypes.

Conclusions:

  • Nasal calcitonin is a promising new treatment for established osteoporosis.
  • It offers a safe and well-tolerated alternative, particularly for patients intolerant to other therapies.
  • Further research on fracture efficacy is warranted, but initial results are encouraging.